CLINICAL TRIALS PROFILE FOR LEVAQUIN

All Clinical Trials for LEVAQUIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00035347 ↗	Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia	Completed	Pfizer	Phase 4	2001-01-01	A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens.
NCT00176306 ↗	Levofloxacin Pharmacokinetics (PK) in the Severely Obese	Completed	Ortho-McNeil Pharmaceutical	Phase 4	2005-01-01	Obesity is known to affect the concentrations of certain medications in the body. Levofloxacin is a commonly used antibiotic. Based on what the investigators know about levofloxacin and how it moves through the body, obesity may affect levofloxacin concentrations. This study aims to show the effect of obesity on levofloxacin concentrations. The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to severely obese, critically ill patients will yield serum concentrations that are likely to be therapeutic.
NCT00176306 ↗	Levofloxacin Pharmacokinetics (PK) in the Severely Obese	Completed	Joel Thompson, PhD	Phase 4	2005-01-01	Obesity is known to affect the concentrations of certain medications in the body. Levofloxacin is a commonly used antibiotic. Based on what the investigators know about levofloxacin and how it moves through the body, obesity may affect levofloxacin concentrations. This study aims to show the effect of obesity on levofloxacin concentrations. The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to severely obese, critically ill patients will yield serum concentrations that are likely to be therapeutic.
NCT00176306 ↗	Levofloxacin Pharmacokinetics (PK) in the Severely Obese	Completed	University of Kentucky	Phase 4	2005-01-01	Obesity is known to affect the concentrations of certain medications in the body. Levofloxacin is a commonly used antibiotic. Based on what the investigators know about levofloxacin and how it moves through the body, obesity may affect levofloxacin concentrations. This study aims to show the effect of obesity on levofloxacin concentrations. The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to severely obese, critically ill patients will yield serum concentrations that are likely to be therapeutic.
NCT00250718 ↗	Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach	Terminated	New Mexico Cancer Care Alliance	Phase 2	2004-10-01	1.1 To determine the efficacy of a combination treatment of VP-16, chlorambucil, dexamethasone, and vincristine in patients with relapsed/refractory hematological malignancies. 1.2 To determine the toxicity profile of the above regimen in this patient population. 1.3 Evaluate the effect of low dose administration of chemotherapy on angiogenesis, and correlate this with tumor responses.
NCT00617591 ↗	Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)	Completed	Celgene Corporation	Phase 2	2008-01-01	The purpose of the research study is to determine the response rates when Revlimid® is combined with Doxil® and Dexamethasone (Dd-R) in newly diagnosed Multiple Myeloma. The study will also evaluate the side effects caused by the combination of these three drugs. This therapy is investigational in the treatment of Multiple Myeloma. Revlimid® is a drug that alters the immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. Revlimid® is approved by the Food and Drug Administration (FDA) for specific types of myelodysplastic syndrome (MDS) and Multiple Myeloma, two different types of blood cancer. It is currently being tested in a variety of other cancer conditions. In this case it is considered experimental. Doxil® is a form of chemotherapy. It is approved by the FDA for the treatment of relapsed/ refractory Multiple Myeloma in combination with Velcade. Dexamethasone is a steroid. It is also approved by the FDA, but not for the treatment of Multiple Myeloma. It is considered a standard part of most myeloma therapies for newly diagnosed patients.

Clinical Trial Conditions for LEVAQUIN

Condition Name

Condition Name for LEVAQUIN
Intervention	Trials
Neutropenia	1
Sarcoidosis; Antimycobacterial Therapy;	1
Chronic Sinusitis - Ethmoidal Anterior	1
Critical Illness	1

Condition MeSH

Condition MeSH for LEVAQUIN
Intervention	Trials
Infection	4
Pneumonia	4
Urinary Tract Infections	4
Communicable Diseases	4

Clinical Trial Locations for LEVAQUIN

Trials by Country

Trials by Country for LEVAQUIN
Location	Trials
United States	127
Canada	13
Georgia	4
Ukraine	3
Latvia	3

Trials by US State

Trials by US State for LEVAQUIN
Location	Trials
Florida	7
California	7
Texas	6
Ohio	6
New York	6

Clinical Trial Progress for LEVAQUIN

Clinical Trial Phase

Clinical Trial Phase for LEVAQUIN
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	6
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for LEVAQUIN
Clinical Trial Phase	Trials
Completed	15
Terminated	3
Unknown status	2

Clinical Trial Sponsors for LEVAQUIN

Sponsor Name

Sponsor Name for LEVAQUIN
Sponsor	Trials
Pfizer	2
Westat	2
Boston University	2

Sponsor Type

Sponsor Type for LEVAQUIN
Sponsor	Trials
Other	33
Industry	16
NIH	5

Levaquin (levofloxacin) Clinical Trials Update, Market Analysis, and Expedited Market Projections

Last updated: July 27, 2026

Levaquin is a legacy fluoroquinolone brand (levofloxacin) whose US exclusivity has long lapsed; current competitive dynamics are driven by generic availability, label-expansion history, resistance trends, and payer utilization. The drug’s market is projected to remain constrained versus earlier years due to mature generic competition, tighter fluoroquinolone stewardship, and shifting clinical preferences toward alternative anti-infectives and stewardship-led restrictions.

What clinical trials are still running for Levaquin (levofloxacin) and what endpoints matter?

Direct answer: Ongoing “Levaquin” branded clinical trials are limited in scope today; most current activity is expected to be post-marketing, comparative effectiveness, antimicrobial stewardship evaluations, or trials using levofloxacin within broader regimens rather than as a new lead asset. For market-moving signals, the highest-impact endpoints are resistance, microbiologic eradication, and safety in real-world or stewardship-controlled populations (tendinopathy, neuropathy, QT-risk subgroups).

Which trial types typically remain for levofloxacin in 2024–2026?

• Comparative infection trials against other standard-of-care agents in specific indications (community-acquired pneumonia, acute bacterial sinusitis, complicated UTIs, prostatitis).
• Pharmacokinetic or formulation-bioequivalence trials for generic entrants (these rarely create brand value but affect market share).
• Observational registries tracking fluoroquinolone safety signals and antimicrobial use patterns.

What endpoints influence adoption despite generic availability?

• Treatment success rates and microbiologic eradication at test-of-cure.
• Rates of adverse events tied to fluoroquinolone warnings: tendinopathy/rupture, peripheral neuropathy, CNS effects, dysglycemia, and QT prolongation.
• Stewardship compliance metrics (appropriateness criteria adherence).

How do the FDA labels for Levaquin (levofloxacin) shape ongoing prescribing and trial relevance?

Direct answer: Current prescribing patterns reflect the FDA-approved indications and the safety label constraints added over time. Even without new exclusivity, label language and stewardship interpretations drive usage volumes, especially where alternative antibiotics are available.

Key label categories that typically drive utilization

• Respiratory infections: community-acquired pneumonia, acute bacterial sinusitis, acute exacerbation of chronic bronchitis (where applicable by label).
• Genitourinary infections: complicated urinary tract infections, including pyelonephritis; prostatitis.
• Off-label use historically existed, but payer and stewardship controls reduce broad use.

How do safety warnings affect market behavior?

• Increased prescriber caution reduces “default” fluoroquinolone selection, especially in lower-risk indications where alternatives exist.
• Higher monitoring and prior authorization frequency in some payer formularies can reduce volume even when pricing is low.

What is the Orange Book status of Levaquin (levofloxacin) and how many patents remain relevant?

Direct answer: Levaquin’s branded patent estate is not expected to be a gating factor for generic market entry in major geographies. The product’s commercial reality is dominated by generic levofloxacin formulations and facility-level manufacturing permissions.

Practical implications for exclusivity

• In the US, the brand’s market access is primarily governed by expired composition-of-matter and formulation exclusivity, leaving generic competition as the default structure.
• For any remaining patent relevance, it would more likely relate to specific formulation tweaks, manufacturing processes, or method-of-use claims tied to particular labeling rather than the core levofloxacin active.

When does Levaquin lose exclusivity and what does that mean for market size?

Direct answer: Branded exclusivity for Levaquin has already expired. The market after exclusivity tends to settle into a stable generic-volume share with periodic volatility driven by antibiotic stewardship, resistance cycles, and safety-related prescribing shifts.

Market structure after exclusivity

• Pricing compresses quickly after generic launch.
• Share consolidates among a smaller set of low-cost suppliers capable of maintaining supply continuity.
• Any temporary uplift is usually linked to:
  • formulary disruptions at suppliers,
  • shortages,
  • or shifts in clinical practice during respiratory infection surges.

What generic entry risks exist for levofloxacin (and how do they affect Levaquin’s market share)?

Direct answer: Generic entry is largely “done” for levofloxacin, but ongoing risks include supply constraints and quality-system issues at key manufacturers. These events can create short-lived share shifts away from specific NDCs, not long-term brand value.

What matters commercially now

• Supply stability and lead times for oral and IV levofloxacin SKUs.
• Contracting and rebates with pharmacy benefit managers.
• Payer policies that restrict fluoroquinolone use in certain indications.

How does Levaquin compare with other fluoroquinolones and alternative anti-infectives?

Direct answer: Levaquin competes within a broader fluoroquinolone class and against other antibiotic classes. Market share depends more on payer restrictions, stewardship protocols, and formulary preference than on brand-level differentiation.

Competitor set (class and substitute)

• Fluoroquinolones: ciprofloxacin, moxifloxacin, and others depending on indication.
• Substitutes: beta-lactams (where clinically appropriate), macrolides, doxycycline in certain contexts, and other respiratory or UTI-specific antibiotics.

What typically drives substitution away from fluoroquinolones

• Safety concerns and stewardship flags.
• Local resistance patterns that reduce expected effectiveness.
• Availability and relative cost of alternative regimens.

What is the current market for Levaquin (levofloxacin): size, growth drivers, and downside risks?

Direct answer: The market is mature and price-compressed due to generic competition. Growth is limited, and performance is more sensitive to:

• seasonal respiratory infection volume,
• stewardship restrictions,
• safety signal management,
• and supplier supply continuity.

Core growth drivers

• Respiratory infection demand surges each season (if payer access permits).
• Use in clinically indicated high-susceptibility contexts where levofloxacin remains a guideline-supported option.

Core downside risks

• Stewardship-led down-titration in non-severe indications.
• Continued scrutiny tied to adverse event warnings that shift prescribing toward alternatives.
• Supply interruptions at key generic manufacturers that can either temporarily lift prices or disrupt treatment.

How do clinical and regulatory changes affect utilization of Levaquin after label warnings?

Direct answer: Post-warning dynamics show that utilization is sticky once protocols are embedded, even when pricing is low. Trials and evidence that reduce uncertainty about safety in specific populations can improve utilization, but they are unlikely to restore “brand-like” economics.

Populations where utilization is most sensitive

• Older adults at higher risk for tendon, CNS, dysglycemia, or QT-related events.
• Patients with comorbidities or concomitant QT-prolonging medications.
• Patients with prior antibiotic exposure where resistance patterns affect decision-making.

What manufacturing and supply chain factors drive market volatility for levofloxacin?

Direct answer: Market volatility for generic levofloxacin is frequently tied to upstream API supply, facility capacity, and FDA inspection outcomes. Brand recovery is not the main mechanism; instead, NDC availability changes can move share between generic suppliers.

Commercial consequences

• Temporary shortages raise prices and can trigger formulary substitutions.
• Long lead times can cause hospitals to standardize on alternative antibiotics.

How strong is the competitive position for levofloxacin in respiratory and UTI indications?

Direct answer: Competitive strength remains where clinicians need oral-to-IV flexibility, dosing convenience, and reliable coverage for organisms in local antibiograms. The brand’s role is secondary to generics and procurement contracts.

Respiratory infections

• Fluoroquinolones can retain relevance for specific severity or resistance contexts.
• Market risk comes from guideline evolution and stewardship restrictions.

UTIs/prostatitis

• Adoption depends on susceptibility, severity, and outpatient appropriateness policies.
• Safety considerations can reduce “first-line” selection where alternatives exist.

Levaquin clinical trials update: what should investors track in upcoming readouts?

Direct answer: For levofloxacin, the highest signal-to-noise for market impact comes from studies that change practice in measurable ways: real-world safety outcomes under stewardship, comparative effectiveness in specific subpopulations, and resistance-driven guidance updates.

High-impact tracking items

• Studies that quantify adverse-event rates under protocol-based prescribing.
• Surveillance evidence linking regimen choice to outcomes in resistant cohorts.
• Hospital formulary policy changes tied to safety and resistance.

Key tables: what matters for market projection of Levaquin (levofloxacin)

1) Market drivers and expected directional impact

Factor	Direction for demand	Time horizon	Primary mechanism
Generic price compression	Down	Ongoing	Margin erosion, stable volume
Stewardship restrictions	Down	Ongoing	Reduced non-severe use
Respiratory seasonal demand	Up	Short-term	Volume increase during surges
Resistance pattern shifts	Up/Down	Medium	Coverage effectiveness vs alternatives
Safety signal perception	Down	Ongoing	More restrictive prescribing
Supplier continuity/shortage	Up/Down	Short-term	Availability-driven prescribing changes

2) Market projection logic (qualitative framework)

Scenario	Demand	Price	Supplier share	Probability (baseline)
Baseline (mature generics, stewardship steady)	Flat to slight down	Low, stable	Consolidated among major suppliers	High
Better stewardship-managed safety evidence	Slight up	Low	Incremental shift back in restricted niches	Medium
Resistance reduces effectiveness vs substitutes	Down	Low	Substitution to alternatives	Medium
Supplier shortage at key generics	Up short-term	Up short-term	Temporary share shift	Low to Medium

What is the forecast for Levaquin revenue and how does it compare with generic levofloxacin?

Direct answer: A sustained branded-revenue recovery is not the base case. The “asset” is better modeled as generic levofloxacin market dynamics: flat-to-declining volumes with low pricing and event-driven spikes from seasonal infection demand and supply constraints.

Revenue outlook positioning

• Branded Levaquin revenue: structurally limited by generic dominance.
• Generic levofloxacin market: stable to slightly declining overall, with volatility from infection seasonality and supply.

Key Takeaways

• Levaquin’s clinical-trial activity is unlikely to change the fundamental market structure; generic competition dominates.
• Utilization is governed by FDA labeling history, safety warnings, and stewardship protocols more than by branded clinical innovation.
• Market performance is most sensitive to seasonal respiratory demand, resistance-guided selection, and supply continuity of generic levofloxacin.
• Near-term market projection should treat branded value as constrained and model volume more than price.

FAQs

1) Are there any ongoing Levaquin branded clinical trials with results that could shift prescribing?
Branded-driving results are limited; the highest-impact evidence typically comes from post-marketing safety and real-world comparative studies.

2) Does levofloxacin’s safety label affect hospital formularies and prior authorization?
Yes, stewardship and payer policies commonly incorporate fluoroquinolone safety concerns into formulary management.

3) How do levofloxacin shortages typically affect market pricing and NDC share?
Shortages tend to increase prices and shift share among available suppliers, often temporarily.

4) Which indications drive remaining levofloxacin utilization in the generic era?
Respiratory infections in specific severity/resistance contexts and selected UTIs/prostatitis cases where levofloxacin remains suitable.

5) How does resistance change levofloxacin market share versus alternatives?
Resistance decreases expected effectiveness and increases substitution to beta-lactams, macrolides, doxycycline, or other regimen options depending on antibiograms.

References

1. US Food and Drug Administration. Levaquin (levofloxacin) prescribing information and labeling history (accessed via FDA Drugs@FDA database).
2. FDA. Drugs@FDA database for levofloxacin (Levaquin) application and labeling references.
3. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (accessed for levofloxacin listings).